Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Marketed
  6. Launches

Launches

Thumbnail
May 20, 2022

Pfizer and its Sidekick snare a new approval

Thumbnail
May 16, 2022

Diabetes approval fires the gun on Lilly blockbuster

Article image
Vantage logo
May 03, 2022

Screen time for Guardant

Article image
Vantage logo
February 10, 2022

Seagen delivers a triple blow

Article image
Vantage logo
February 04, 2022

Lilly and Roche learn from Biogen’s mistakes

As Biogen continues to provide a case study in how not to launch a drug, Lilly and Roche insist the focus must remain on pivotal readouts.

Article image
Vantage logo
December 23, 2021

Argenx’s independent streak approaches its biggest test

Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.

Article image
Vantage logo
December 02, 2021

The T-cell test bronze goes to Qiagen

Article image
Vantage logo
November 17, 2021

EU steers clear of Aduhelm as a bigger headache threatens

Aduhelm’s likely EU rejection comes amid a key senior executive departure and federal inquiry, and the drug now faces a crucial Medicare decision.

Article image
Vantage logo
November 03, 2021

Novo fattens up again

But competition in obesity is looming.

Article image
Vantage logo
October 21, 2021

As Aduhelm forecasts plunge, all eyes turn to coverage decision

Article image
Vantage logo
September 14, 2021

Astellas readies roxadustat for launch

But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.